Kovack Advisors Inc. Boosts Stake in Nyxoah S.A. (NASDAQ:NYXH)

Kovack Advisors Inc. grew its stake in Nyxoah S.A. (NASDAQ:NYXH) by 100.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Kovack Advisors Inc.’s holdings in Nyxoah were worth $160,000 as of its most recent filing with the Securities and Exchange Commission.

Analyst Ratings Changes

A number of research analysts have issued reports on NYXH shares. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a report on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Nyxoah Stock Down 2.0 %

NYXH stock opened at $10.04 on Monday. The firm has a market cap of $341.96 million, a PE ratio of -5.37 and a beta of 1.41. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The firm’s fifty day moving average is $9.93 and its 200 day moving average is $9.07. Nyxoah S.A. has a one year low of $6.76 and a one year high of $20.00.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.